BACE-1 inhibitors part 2: Identification of hydroxy ethylamines (HEAs) with reduced peptidic character

Brian Clarke(GlaxoSmithKline (United Kingdom)), Gareth Wayne(GlaxoSmithKline (United Kingdom)), Julie A. Hawkins(Charles River Laboratories (United Kingdom)), J. Mosley(GlaxoSmithKline (United Kingdom)), Sharon Sweitzer(GlaxoSmithKline (United States)), David Riddell(Eli Lilly (United States)), John M. Ward(University College London), Sally Redshaw(GlaxoSmithKline (United Kingdom)), Steven J. Stanway(GlaxoSmithKline (United Kingdom)), V. Soleil(GlaxoSmithKline (United Kingdom)), Ishrut Hussain(GlaxoSmithKline (United Kingdom)), David T. MacPherson(GlaxoSmithKline (United Kingdom)), Pam Theobald(GlaxoSmithKline (United Kingdom)), Emmanuel H. Demont(Age UK), G. Maile(GlaxoSmithKline (United Kingdom)), Peter H. Milner(GlaxoSmithKline (United Kingdom)), Alan Naylor(GlaxoSmithKline (United Kingdom)), D. Vesey(GlaxoSmithKline (United Kingdom)), R. Dunsdon(GlaxoSmithKline (United Kingdom)), Alistair O’Brien(GlaxoSmithKline (United Kingdom)), Paul Rowland(GlaxoSmithKline (United Kingdom)), Daryl S. Walter(GlaxoSmithKline (United Kingdom)), Geoffrey Stemp(GlaxoSmithKline (United Kingdom)), Colin Dingwall(GlaxoSmithKline (United Kingdom)), Andrew Faller(GlaxoSmithKline (United Kingdom)), Kathrine J. Smith(GlaxoSmithKline (United Kingdom)), Rosalie Matico(GlaxoSmithKline (United States))
Bioorganic & Medicinal Chemistry Letters
January 2, 2008
Cited by 57


Related Papers